Summary
Braveheart Bio has collected $185 million from leading biotech investors to start registration-enabling studies for a cardiovascular drug it licensed from Hengrui, one of the
Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsl…
Source: Endpoints News
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
